Statins: underused by those who would benefit.
作者信息
Hulley S B, Grady D, Browner W S
机构信息
Department of Epidemiology, Biostatistics, and Medicine, University of
出版信息
BMJ. 2000 Oct 21;321(7267):971-2. doi: 10.1136/bmj.321.7267.971.
Abstract
摘要
相似文献
1
Statins: underused by those who would benefit.他汀类药物：能从中获益的人群未充分使用。
BMJ. 2000 Oct 21;321(7267):971-2. doi: 10.1136/bmj.321.7267.971.
2
Consensus statement: Role of therapy with "statins" in patients with hypertriglyceridemia.共识声明：“他汀类药物”治疗在高甘油三酯血症患者中的作用
Am J Cardiol. 1998 Feb 26;81(4A):1B-6B. doi: 10.1016/s0002-9149(98)00030-7.
3
Efficacy of low-density-lipoprotein lowering with statins.他汀类药物降低低密度脂蛋白的疗效。
Lancet. 1994 Sep 3;344(8923):683.
4
Efficacy of low-density-lipoprotein lowering with statins.
Lancet. 1994 Sep 3;344(8923):683.
5
[Can the action of statins reveal etiology of coronary diseases?].[他汀类药物的作用能否揭示冠心病的病因？]
Lakartidningen. 2001 Oct 17;98(42):4566-7.
6
Statins and coronary heart disease.他汀类药物与冠心病
Lancet. 1996 Jul 6;348(9019):57. doi: 10.1016/s0140-6736(05)64379-6.
7
What kinds of studies should be required to probe efficacy and safety of drugs in special populations?需要开展哪些类型的研究来探究药物在特殊人群中的疗效和安全性？
Am J Cardiol. 1998 Apr 23;81(8A):84F-87F.
8
Benefits and risks of HMG-CoA reductase inhibitors in the prevention of coronary heart disease: a reappraisal.HMG-CoA还原酶抑制剂在预防冠心病中的获益与风险：一项重新评估
Drug Saf. 1996 Jan;14(1):11-24. doi: 10.2165/00002018-199614010-00003.
9
Coadministration of itraconazole with hypolipidemic agents may induce rhabdomyolysis in healthy individuals.伊曲康唑与降血脂药合用可能会在健康个体中诱发横纹肌溶解症。
Arch Dermatol. 1996 Oct;132(10):1254. doi: 10.1001/archderm.1996.03890340120028.
10
Associations of cholesterol lowering by statins with anger and hostility in hypercholesterolemic men.
Biol Psychiatry. 1994 Apr 15;35(8):575-7. doi: 10.1016/0006-3223(94)90107-4.
引用本文的文献
1
Improvement of Platelet Respiration by Cell-Permeable Succinate in Diabetic Patients Treated with Statins.细胞可渗透琥珀酸盐对接受他汀类药物治疗的糖尿病患者血小板呼吸的改善作用
Life (Basel). 2021 Mar 28;11(4):288. doi: 10.3390/life11040288.
2
Lipid-Lowering Therapy in Patients with Coronary Heart Disease and Prior Stroke: Mission Impossible?冠心病合并既往脑卒中患者的降脂治疗：不可能完成的任务？
J Clin Med. 2021 Feb 22;10(4):886. doi: 10.3390/jcm10040886.
3
Intensity of Lipid Lowering With Statin Therapy in Patients With Cerebrovascular Disease Versus Coronary Artery Disease: Insights from the PALM Registry.他汀类药物治疗在脑血管病与冠状动脉疾病患者中的降脂强度：来自 PALM 登记研究的见解。
J Am Heart Assoc. 2019 Oct;8(19):e013229. doi: 10.1161/JAHA.119.013229. Epub 2019 Sep 26.
4
Prevention of cardiovascular events in elderly people.老年人心血管事件的预防
Drugs Aging. 2005;22(10):859-76. doi: 10.2165/00002512-200522100-00005.
5
Paying for statins.他汀类药物的费用支付。
BMJ. 2004 Feb 14;328(7436):400-2. doi: 10.1136/bmj.328.7436.400.
6
Hypercholesterolemia underdiagnosis and undertreatment in psychiatric patients in Italy.
Eur J Epidemiol. 2003;18(4):373-4. doi: 10.1023/a:1023723631518.
7
Treating the patient or the population? Part 1. Judging the benefit of treatment of individual patients.治疗个体患者还是群体？第一部分：评判个体患者的治疗益处
West J Med. 2001 Jul;175(1):35-7. doi: 10.1136/ewjm.175.1.35.
本文引用的文献
1
Use of lipid lowering drugs for primary prevention of coronary heart disease: meta-analysis of randomised trials.使用降脂药物进行冠心病一级预防：随机试验的荟萃分析。
BMJ. 2000 Oct 21;321(7267):983-6. doi: 10.1136/bmj.321.7267.983.
2
Follow-up study of patients randomized in the Scandinavian simvastatin survival study (4S) of cholesterol lowering.对在斯堪的纳维亚辛伐他汀生存研究（4S）中随机分组的患者进行的随访研究，该研究旨在降低胆固醇。
Am J Cardiol. 2000 Aug 1;86(3):257-62. doi: 10.1016/s0002-9149(00)00910-3.
3
Cost-effectiveness of cholesterol-lowering therapies according to selected patient characteristics.根据选定的患者特征评估降胆固醇治疗的成本效益。
Ann Intern Med. 2000 May 16;132(10):769-79. doi: 10.7326/0003-4819-132-10-200005160-00002.
4
What is the optimal age for starting lipid lowering treatment? A mathematical model.开始降脂治疗的最佳年龄是多少？一个数学模型。
BMJ. 2000 Apr 22;320(7242):1134-40. doi: 10.1136/bmj.320.7242.1134.
5
Coronary and cardiovascular risk estimation for primary prevention: validation of a new Sheffield table in the 1995 Scottish health survey population.一级预防的冠心病和心血管疾病风险评估：1995年苏格兰健康调查人群中一种新的谢菲尔德表格的验证
BMJ. 2000 Mar 11;320(7236):671-6. doi: 10.1136/bmj.320.7236.671.
6
Guidelines on preventing cardiovascular disease in clinical practice.临床实践中预防心血管疾病指南。
BMJ. 2000 Mar 11;320(7236):659-61. doi: 10.1136/bmj.320.7236.659.
7
Undertreatment of hyperlipidemia in the secondary prevention of coronary artery disease.冠心病二级预防中高脂血症的治疗不足。
J Gen Intern Med. 1999 Dec;14(12):711-7. doi: 10.1046/j.1525-1497.1999.02229.x.
8
Are drugs within a class interchangeable?
Lancet. 1999 Oct 2;354(9185):1202-4. doi: 10.1016/S0140-6736(99)03190-6.
9
Treatment patterns and distribution of low-density lipoprotein cholesterol levels in treatment-eligible United States adults.符合治疗条件的美国成年人的治疗模式及低密度脂蛋白胆固醇水平分布
Am J Cardiol. 1998 Jul 1;82(1):61-5. doi: 10.1016/s0002-9149(98)00227-6.
10
Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study.洛伐他汀对胆固醇水平正常的男性和女性急性冠脉事件的一级预防：空军/德州冠状动脉粥样硬化预防研究（AFCAPS/TexCAPS）的结果
JAMA. 1998 May 27;279(20):1615-22. doi: 10.1001/jama.279.20.1615.
Zotero 插件